ADT

Cognition and Hormone Therapy (ADT)

There have been numerous studies examining the how hormone deprivation (ADT), in the treatment of prostate cancer, has on a man’s cognition. There have been contradictor studies about this issue, however having had the experience and the honor of dealing with so many men with prostate cancer treated with androgen deprivation therapy (ADT), as well [...]

Degarelix or Leuprolide – Today’s Question Explored

There are many different types of drugs used for hormone therapy in the treatment of prostate cancer. One of the newer classes of drugs include the GnRH antagonists. Degarelix (aka Firmagon) is the one drug in this class that is currently approved for prostate cancer. Degarelix, like the other hormone therapy drugs, was developed to [...]

Hormone Therapy (ADT) for Prostate Cancer Patients Might Provide Us Another Long Term Gift – Alzheimer’s Disease

Hormone therapy (ADT) is notorious for providing us with side effects. Some of these side effects are best described as ones that deteriorate our general quality of life. For example the most common one we all are familiar with is, of course, hot flashes. You could also add erectile dysfunction as well as loss of [...]

Pamorelin (Trelstar) Now Available in the Philippines

Pamorelin (Trelstar® )is going to become available in the Philippines. Pamorelin, and Decapeptyl® will be made available to urologists and oncologists who treat men with advanced prostate cancer. It will be available in one, three and six month formulations. Pamorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). It is designed to chemically [...]

How To Have A Firmagon Injection And Minimized The Side Effects

Three of the participants on the Malecare Health Unlocked Advanced Prostate Cancer Online Support Group have been sharing their personal experiences and recommendations on how to best get a Firmagon injection. It is clear that how the injection is given has a direct effect on he pain and inflammation a man will experience from the [...]

Be Cautious Taking Megace To Treat Hormone Therapy Hot Flashes

When taking hormone therapy (ADT) each of us experiences different side effects and each of us experiences them differently.  Anyone experiencing hot flashes, probably the most commonly reported side effect of ADT during hormone therapy (ADT) knows how difficult, embarrassing and uncomfortable they can become as you go through your life. Some men, who find [...]

Understanding the Reality of the Side Effects from Early Chemotherapy

Ever since the research showing that men who are newly diagnosed with very aggressive prostate cancer have a significant life extension advantage if they move immediately to chemotherapy (with docetaxel) along with hormone therapy (ADT) there has been, what I can only describe as a paradigm shift in the clinical care of men with metastatic [...]

Early Hormone Therapy In Men With A Rising PSA Live Longer Then Men Who Delay Therapy – A Phase 3 Trial

The standard of care is to offer androgen deprivation therapy (ADT) to men with prostate cancer who have a rising prostate specific antigen (PSA) after an attempt to cure their cancer with primary therapy that has failed (PSA relapse) or in men who are considered not suitable for curative treatment. The question is what is [...]

Transdermal Estrogen Is Good For Hot Flash Mitigation and For Hormone Therapy (ADT)

Yesterday's post about the use of transdermal estrogen patches as an alternative to LHRHa drugs  elicited a question on the Malecare Health Unlocked Advanced Prostate Cancer Online Support Group.  The question raised, or I should say the comment made was that estrogen is used for the purposes of hot flash mitigation and the use of [...]

Side Effects and Toxicity in a Multi-modality Approach Post Radical Prostatectomy with Radiation and ADT

The optimal use and timing of secondary therapy after radical prostatectomy remains controversial despite some new findings supporting the advantages of using aggressive combined secondary therapies was presented at the most recent ASCO GU conference in San Francisco. There are limited data on the patient-reported outcomes following multimodality therapy. Given the move towards increasing combination [...]